Iatrogenic deaths in hereditary fructose intolerance

The rarity of a disease provides little reassurance for those who suffer from it. Hereditary fructose intolerance (HFI) was described more than 35 years ago but fatal cases (sometimes related to the medicinal use of fructose based intravenous solutions) continue to occur. Given that the disorder responds to dietary treatment and is compatible with a normal duration of life, how do these tragedies arise?

Best known to paediatricians, HFI characteristically presents with vomiting, symptomatic hypoglycaemia, and failure to thrive during weaning or on transfer from breast milk to fruit juice or artificially sweetened feeds. The affected infant has feeding difficulties and episodes of disturbed consciousness or even hypoglycaemic seizures occur. Should administration of fructose, or the related sugars sucrose or sorbitol continue, chronic intoxication results: there is jaundice, liver enlargement, renal tubular dysfunction, and a haemorrhagic tendency accompanying hepatic failure that leads to death.1,2

The abundance of sucrose and fructose in infant foods renders survival dependent on significant reductions of sugar intake: the mother may identify preparations that provoke symptoms or the infant itself develops an aversion to sweet tasting foods and drinks. Avoidance of sweet comestibles was noted by Chambers and Pratt who, first reporting 'idiomsyn- crasy to fructose' in a 24 year old woman, observed that she could take glucose without ill effect but did not enjoy the taste.1 Before diagnosis, most adults with HFI ingest only a few grams of fructose or sucrose per day – a fraction of that consumed by healthy individuals – and dental caries is rare.1

None the less, they continue to suffer abdominal symptoms and hypoglycaemia intermittently as a result of accidental dietary indiscretions. Although chronic intoxication with fructose has been considered unlikely after institution of a restricted diet, rigorous studies in children with HFI show that growth retardation accompanied by biochemical abnormalities occurs unless dietary fructose is reduced to less than 40 mg per kilogram body weight per day.4

HFI is transmitted as an autosomal recessive trait with an estimated frequency of one in 20,000 live births.7 The disease is caused by genetic defects in the specialised enzyme of fructose metabolism, aldolase B.7 Aldolase B is expressed in the liver, small intestine, and proximal renal tubule where it facilitates assimilation of dietary fructose by catalysing the cleavage of fructose-1-phosphate.8 In the absence of fructose – either ingested as the free sugar or derived from sucrose or sorbitol – patients with HFI suffer no ill effects but exposure to small amounts of this sugar induces functional impairment, for example renal tubular acidosis,9 and eventually structural injury in the tissues that are sites for its metabol- ism.

The mechanisms of fructose toxicity are complex: intracellular sequestration of fructose-1-phosphate depletes the intracellular pool of free inorganic phosphate (as shown by 31P magnetic resonance spectroscopy in vivo) and these effects inhibit glycolgenolysis and gluconeogenesis leading to refractory hypoglycaemia.10 Feedback inhibition of ketohexokinase reduces the further metabolism of fructose so that when the renal threshold is exceeded this reducing sugar...
appears in the urine: fructosaemia is an obsolescent term for this disorder. Hyperuricaemia and hyperuricosuria result from degradation of adenine nucleotides within the liver and reflect accumulation of adenosine deaminase by reduced intracellular concentrations of free inorganic phosphate. Breakdown of nucleotides that exist as preformed magnesium ion complexes causes loss of energy charge and critically impairs cellular metabolism. The cause of tissue injury resulting from continued exposure to fructose in HFI is unknown but acute experimental challenge induces ultrastructural changes in the liver and jejunum. The appearance of amorphous deposits and concentric membranous arrays suggests that autophagocytosis with lysosomal accumulation of fructose-1-phosphate may contribute.

Parenteral administration of fructose based solutions, including invert sugar and sorbitol (that is rapidly converted to fructose by sorbitol dehydrogenase in the liver), to patients with HFI causes acute liver cell necrosis and profound metabolic acidosis. At least 15 fatal cases with irreversible hepatorenal failure have been reported from several countries and many others are known. Once popular as a nutrient in postoperative intravenous fluids, for children and for parenteral hyperalimentation, the use of fructose in most countries has declined markedly since the late 1970s. However, in continental Europe, especially in German speaking countries, sorbitol or fructose solutions are routinely administered during surgery. In the last decade, all instances of severe poisoning with fructose and iatrogenic death in HFI have been reported from Germany or Austria. The correlation between prescribing practice and outcome is striking: it should convince concomitant paediatricians and physicians elsewhere that HFI is not over represented in Germany, Switzerland, or Austria. Given also that these tragic accidents occur in older children and adults, the conclusion that many patients with HFI survive infancy and, as a result of self imposed dietary restriction, live to adulthood eluding formal diagnosis, appears to be inescapable.

The emergence of sucrose as a commodity as well as a major constituent of Western style diets has its roots in the colonial and industrial history of cane sugar and, later, beet sugar. In contrast, the rise of fructose as a fashionable nutrient for medicinal use has been short lived. Feeding experiments by Minkowski in the last century showed that fructose could be assimilated rapidly after pancreaticotomy and confirmed that this sugar was preferentially metabolised by patients with diabetes mellitus. That fructose uptake by the liver was independent of insulin, and that this sugar (less irritant to the veins than equally concentrated solutions of glucose) was more rapidly utilised, were further theoretical advantages. Studies showing that fructose has less effect on blood sugar concentrations in postoperative patients and diabetic subjects than equivalent amounts of glucose, led to its widespread use as a parenteral nutrient. Fructose and its precursor, sorbitol, have been advocated for the treatment of diabetic ketoacidosis for parenteral nutrition in adults and, in the form of invert sugar, for children.

Later, hyperuricaemia reflecting nucleotide degradation and severe lactic acidosis resulting from administration of fructose in patients without HFI were documented; many authors have warned of its dangers — especially in the critically ill. In most countries these warnings have been heeded and although fructose and sorbitol are still used as sweeteners and sugar substitutes in diabetic foods, parenteral preparations have fallen from favour.

HFI provides a vivid example of how genetic and dietary factors, modified by eating behaviour, interact to cause disease. Molecular analysis of aldolase B genes from patients with HFI originating from many countries has shown that a few point mutations account for more than 85% of defective alleles. Well over one half of these disease alleles are accounted for by one mutation that is readily detected and widely distributed. Until now, no simple test for the diagnosis of HFI has been available: diagnosis has relied on the intravenous fructose tolerance test or enzymatic assay of fructaldolase activities in liver tissue intestinal mucosa obtained by biopsy. Latterly, the use of mutation specific oligonucleotide probes has facilitated diagnosis of HFI in individuals with symptoms by direct analysis of DNA amplified in the polymerase chain reaction (PCR).

PCR based methods of DNA analysis for forensic diagnosis are now well established. A recent report of investigations after the unexpected death of an Italian girl after appendectomy confirms their power. The patient, who like a surviving brother, had had a long disaste for fruit and sweets, was treated in Germany, where she received intravenous sorbitol and fructose during and after surgery. She died as a result of acute hepatoportal failure. Sequence analysis of DNA from the brother identified two unusual mutations giving rise to null alleles of aldolase B. Molecular analysis of DNA obtained from a fragment of necrotic liver that had been obtained postmortem by needle aspiration, fixed and embedded for histological examination, confirmed the presence of both mutations and the cause of death.

The lethal effects of parenteral fructose in patients with HFI at all ages are well recognised but indiscriminate use of fructose based solutions in patients with dietary intolerance of this sugar, though often recorded, is surely indefensible. In countries where traditional prescribing practices and commercial influences promote the routine administration of fructose, there is a clear duty (as with the avoidance of repeated halothane use) to take a history first. Several instances of parent-to-offspring transmission of HRI (a recessive disease) indicate that mutant alleles of aldolase B occur with an appreciable frequency in the population. Fructose intolerance resembles phenylketonuria: it occurs with similar frequency and responds completely to appropriate dietary treatment. For these reasons, population screening for HFI before weaning may be justified as the most common mutations can be easily detected by PCR based methods. Pilot studies to determine the usefulness of screening could be based on population archives in the form of the Guthrie blood spot provide unbiased samples of DNA. Sweeter fruits to come from the application of molecular genetics?

TIMOTHY M COX

Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ

Iatrogenic deaths in hereditary fructose intolerance